T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival

Journal of Surgical Oncology

Volumn 112, Issue 4, 2015, Pages 430-435

  Yang, Meng ^a   Yu, Qinchao ^a   Liu, Jing ^a   Fu, Weiwei ^a   Cao, Yanwei ^a   Yu, Lun ^a   Shao, Shixiu ^a   Wang, Xinsheng ^a   Niu, Haitao ^a   Wang, Yonghua ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

bladder urothelial carcinoma; PD 1; prognosis; Tim 3

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; T CELL IMMUNOGLOBULIN MUCIN 3 PROTEIN; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; SURVIVAL; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; UROTHELIUM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84942295671     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24012     Document Type: Article

References (27)

1. Babjuk M, Burger M, Zigeuner R, et al.,: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013; 64: 639-653.
2. Herr HW, Bean MA, Whitmore WF Jr,: Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture. Cancer Res 1976; 36: 2754-2760.
3. Mukamel E, Shohat B, Servadio C,: Immunological profile of patients with transitional cell carcinoma of the bladder. Br J Urol 1982; 54: 11-15.
4. Nirschl CJ, Drake CG,: Molecular pathways: Coexpression of immune checkpoint molecules: Signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013; 19: 4917-4924.
5. Wu FH, Yuan Y, Li D, et al.,: Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway. Oncol Rep 2010; 24: 693-699.
6. Jiang J, Jin MS, Kong F, et al.,: Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PloS One 2013; 8: e81799.
7. Zhuang X, Zhang X, Xia X, et al.,: Ectopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol 2012; 137: 978-985.
8. Cao Y, Zhou X, Huang X, et al.,: Tim-3 expression in cervical cancer promotes tumor metastasis. PloS One 2013; 8: e53834.
9. Piao YR, Piao LZ, Zhu LH, et al.,: Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer. Asian Pac J Cancer Prev 2013; 16: 3897-3901.
10. Anderson AC,: Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012; 24: 213-216.
11. Budwit-Novotny DA, McCarty KS, Cox EB, et al.,: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986; 46: 5419-5425.
12. Lee HY, Li CC, Huang CN, et al.,: INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract. J Surg Oncol 2015; 111: 414-422.
13. Wang YH, Cao YW, Yang XC, et al.,: Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. Asian Pac J Cancer Prev 2014; 15: 1321-1326.
14. Tsujihashi H, Matsuda H, Uejima S, et al.,: Immunoresponse of tissue infiltrating lymphocytes in bladder tumors. J Urol 1989; 141: 1467-1470.
15. Bevers RF, Kurth KH, Schamhart DH,: Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004; 91: 607-612.
16. Kastelan Z, Lukac J, Derezic D, et al.,: Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res 2003; 23: 5185-5189.
17. Loskog A, Ninalga C, Paul-Wetterberg G, et al.,: Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007; 177: 353-358.
18. Monney L, Sabatos CA, Gaqlia JL, et al.,: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-541.
19. Yan J, Zhang Y, Zhang JP, et al.,: Tim-3 expression defines regulatory T cells in human tumors. PLoS One 2013; 8: e58006.
20. Hanahan D, Weinberg RA,: The hallmarks of cancer. Cell 2000; 100: 57-70.
21. Folkman J,: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29: 15-18.
22. Wu FH, Yuan Y, Li D, et al.,: Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway. Oncol Rep 2010; 24: 693-699.
23. Tumeh PC, Harview CL, Yearley JH, et al.,: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
24. + T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
25. Zhou Q, Munger ME, Veenstra RG, et al.,: Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117: 4501-4510.
26. Sakuishi K, Apetoh L, Sullivan JM, et al.,: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194.
27. Ngiow SF, von Scheidt B, A, kiba H, et al.,: Anti-TIM3 antibody promotes T cell IFN-γ-mediated anti-tumor immunity and suppresses established tumors. Cancer Res 2011; 71: 6567-6571.